A large GWAS meta‑analysis spanning more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis of indeterminate potential (CHIP) and decreases leukemia risk. Published in Science, the paper links the protective allele to reduced activity of the musashi RNA‑binding protein MSI2 by disrupting a GATA‑2 binding site in hematopoietic stem cells. Functional validation used gene‑edited human HSCs and mechanistic assays showing attenuated clone expansion. The study provides a human genetic precedent for MSI2 modulation as a strategy to restrain clonal expansion and suggests MSI2 as a potential therapeutic target for preventing age‑related blood cancers.